Please fill out the pre-assessment below before the session begins.

Please enable JavaScript in your browser to complete this form.

1. Which of the following JAK inhibitors approved for patients with MF was also effective in managing anemia in these patients? *

A. Fedratinib
B. Momelotinib
C. Pacritinib
D. Ruxolitinib

2.  What clinical finding most influences the choice between a JAK inhibitor (i.e., momelotinib, pacritinb) with anemia benefit or anemia supportive agent (i.e., ESA, luspatercept, danazol) when treating myelofibrosis-associated anemia?

A. The serum erythropoietin level and iron studies
B. The presence of splenomegaly and symptom burden
C. The mechanism of action of the potential therapy

3. Which patient population is most appropriate for treatment with ropeginterferon alfa-2b in polycythemia vera (PV)?

A. A newly diagnosed patient with PV who is low-risk and well-controlled on phlebotomy alone
B. A young patient with PV who requires cytoreductive therapy and is seeking a treatment with long-term disease-modifying potential
C. An elderly patient with PV and multiple comorbidities who has failed two prior cytoreductive agents
D. A patient with essential thrombocythemia and CALR mutation who is intolerant to aspirin.

Medical Learning Institute Inc
40946 US Highway 19N #602
Tarpon Springs, FL 34689
888.654.2631 (toll-free)
609.333.1693 (direct)

Scroll to Top